Orion predicted strong growth for darolutamide, the prescription prostate-cancer medication it co-developed with Bayer.

Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales ...

The pharmaceuticals and agriculture group Bayer aims to return its pharmaceuticals business to mid-single-digit percentage ...

Secondary US filings for Bayer assets cannot be relied on again to face future patent cliffs, demanding focus on early-stage ...

Bayer's transformation focuses on a revitalized portfolio, strong pipeline, and strategic operational changes for sustained ...

Bayer, looking to bolster its position in both imaging and cardiac medicine, struck a deal to snap up two experimental imaging agents and thereby enter the diagnostic tracers development space. | ...

Bayer has asked the justices to decide whether federal law shields the company from lawsuits over its Roundup herbicide and ...

To promote its newly launched nonhormonal menopause drug, Bayer is linking Lynkuet with a familiar face. The Big Pharma has recruited Gabrielle Union-Wade to serve as a celebrity endorser for the ...

Vividion Therapeutics Inc.'s founding chemist prevailed Thursday over fraud claims linked to the biotech company’s $2 billion ...

Bayer’s shared ownership reshapes how teams work, empowering autonomy and accountability to focus on real value creation across the organisation.